Emphysema

2 trials MedDRA PT
2 Registered trials
0 Recruiting
1 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
B Haematology (ATC B) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase II: 2

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

2 trials
  • Sanofi AATD Inc. Commercial
    HUMAN ALPHA-1-PROTEINASE INHIBITOR IMMUNOGLOBULIN G FUSION PROTEIN, RECOMBINANT; HUMAN ALPHA1-PROTEINASE INHIBITOR
    2023-508084-76-00 5 countries 2024 n=34
    Ended
  • Sanofi AATD Inc. Commercial
    HUMAN ALPHA-1-PROTEINASE INHIBITOR IMMUNOGLOBULIN G FUSION PROTEIN, RECOMBINANT
    2023-508137-14-00 5 countries 2025 n=48
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sanofi AATD Inc. Commercial 2 Phase II 0
New trials by year
2024
1
2025
1
← All indication landscapes